Colangelo M, Di Martino M, Polidoro M, Forti L, Tober N, Gennari A
Gastroenterol Rep (Oxf). 2025; 13:goaf005.
PMID: 39867595
PMC: 11769681.
DOI: 10.1093/gastro/goaf005.
Wang Z, Shi Y, Xiong G, Han M, Chen X
Discov Oncol. 2024; 15(1):773.
PMID: 39692970
PMC: 11655830.
DOI: 10.1007/s12672-024-01683-w.
Iijima N, Nakamura S, Ishii Y, Tatsukawa Y, Ikemoto J, Miyamoto S
Clin J Gastroenterol. 2024; 18(1):176-182.
PMID: 39614950
PMC: 11785620.
DOI: 10.1007/s12328-024-02075-x.
Ceriani R, Colapietro F, Gabbiadini R, Dal Buono A, Pugliese N, Masetti C
J Ultrasound. 2024; .
PMID: 39487923
DOI: 10.1007/s40477-024-00949-x.
Inada H, Miyamoto H, Shinriki S, Oda H, Narahara S, Yoshinari M
Int J Clin Oncol. 2024; 29(12):1908-1915.
PMID: 39297909
DOI: 10.1007/s10147-024-02616-x.
Safety of pressurized intraperitoneal aerosolized chemotherapy in biliary cancer patients with peritoneal metastases.
Li D, Crook C, Chung V, Brar G, Fakih M, Barzi A
Future Oncol. 2024; 20(33):2521-2531.
PMID: 39263892
PMC: 11534098.
DOI: 10.1080/14796694.2024.2394013.
Pan-lysyl oxidase inhibition disrupts fibroinflammatory tumor stroma, rendering cholangiocarcinoma susceptible to chemotherapy.
Burchard P, Ruffolo L, Ullman N, Dale B, Dave Y, Hilty B
Hepatol Commun. 2024; 8(8).
PMID: 39101793
PMC: 11299993.
DOI: 10.1097/HC9.0000000000000502.
Imaging features and management of focal liver lesions.
Kahraman G, Haberal K, Dilek O
World J Radiol. 2024; 16(6):139-167.
PMID: 38983841
PMC: 11229941.
DOI: 10.4329/wjr.v16.i6.139.
Residual biliary intraepithelial neoplasia without malignant transformation at resection margin for perihilar cholangiocarcinoma does not require expanded resection: a dual center retrospective study.
Xu Z, Fan X, Zhang C, Li Y, Jiang D, Hu F
World J Surg Oncol. 2024; 22(1):161.
PMID: 38907218
PMC: 11191332.
DOI: 10.1186/s12957-024-03395-5.
Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation.
Esmail A, Badheeb M, Alnahar B, Almiqlash B, Sakr Y, Khasawneh B
Cancers (Basel). 2024; 16(11).
PMID: 38893067
PMC: 11171350.
DOI: 10.3390/cancers16111946.
PLK1 inhibition leads to mitotic arrest and triggers apoptosis in cholangiocarcinoma cells.
Moolmuang B, Chaisaingmongkol J, Singhirunnusorn P, Ruchirawat M
Oncol Lett. 2024; 28(1):316.
PMID: 38807667
PMC: 11130613.
DOI: 10.3892/ol.2024.14449.
ASO Author Reflections: Exploring Surgical Approaches to Bismuth Type IIIa Hepatoportal Cholangiocarcinoma.
Li G, Zhou B
Ann Surg Oncol. 2024; 31(10):6582-6583.
PMID: 38796591
DOI: 10.1245/s10434-024-15516-1.
Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma.
Kendall T, Overi D, Guido M, Braconi C, Banales J, Cardinale V
JHEP Rep. 2024; 6(6):101067.
PMID: 38699072
PMC: 11060959.
DOI: 10.1016/j.jhepr.2024.101067.
National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma.
Dar F, Abbas Z, Ahmed I, Atique M, Aujla U, Azeemuddin M
World J Gastroenterol. 2024; 30(9):1018-1042.
PMID: 38577184
PMC: 10989497.
DOI: 10.3748/wjg.v30.i9.1018.
Transgelin-2, a novel cancer stem cell-related biomarker, is a diagnostic and therapeutic target for biliary tract cancer.
Jo J, Park S, Chung J, Oh T, Lee H, Chung M
BMC Cancer. 2024; 24(1):357.
PMID: 38509504
PMC: 10953140.
DOI: 10.1186/s12885-024-12082-3.
Serum ITIH5 as a novel diagnostic biomarker in cholangiocarcinoma.
Chen M, Ma J, Xie X, Su M, Zhao D
Cancer Sci. 2024; 115(5):1665-1679.
PMID: 38475675
PMC: 11093185.
DOI: 10.1111/cas.16143.
Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma.
McIntyre S, Preston W, Walch H, Sharib J, Kundra R, Sigel C
JCO Precis Oncol. 2024; 8:e2300534.
PMID: 38394469
PMC: 10901433.
DOI: 10.1200/PO.23.00534.
Survival analysis of laparoscopic surgery and open surgery for hilar cholangiocarcinoma: a retrospective cohort study.
Yin Y, Tao J, Xian Y, Hu J, Li Y, Li Q
World J Surg Oncol. 2024; 22(1):58.
PMID: 38369496
PMC: 10875844.
DOI: 10.1186/s12957-024-03327-3.
Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma.
Sawaisorn P, Gaballa A, Saimuang K, Leepiyasakulchai C, Lertjuthaporn S, Hongeng S
Sci Rep. 2024; 14(1):1291.
PMID: 38221530
PMC: 10788337.
DOI: 10.1038/s41598-024-51794-1.
Cohort study to assess geographical variation in cholangiocarcinoma treatment in England.
Jose S, Zalin-Miller A, Knott C, Paley L, Tataru D, Morement H
World J Gastrointest Oncol. 2024; 15(12):2077-2092.
PMID: 38173436
PMC: 10758644.
DOI: 10.4251/wjgo.v15.i12.2077.